HealthyNCT06806501
Muscle Mass, Quality, and the Menopause: Sex-specific Strategies to Mitigate Sarcopenia in Ageing Populations
An observational study of Healthy, run by University of Nottingham at 1 site in United Kingdom.
Trial summary
Aging causes muscles to often become smaller and weaker resulting in physical frailty and functional impairments, such as difficulty raising from a chair, dressing, and preparing meals. In the UK there is a growing aged population with those >65y expected to increase from 18% of the population in 2016, to 26% by 2066. Read more about this study
- Who is it for?
- Ages 18 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Unilateral Resistance Exercise
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 18 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 29 Jul 2024to Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants will be healthy females aged 18 - 65, who are not on hormonal replacement therapy or hormonal contraceptives and are not participating in regular resistance exercise. Participants will fall into two groups: * Premenopausal, defined as having a menstrual cycle and having plasma follicle-stimulating hormone (FSH) <30 IU/L, taken during days 1-5 of their menstrual cycle. * Postmenopausal, defined as having no menses for 12 months, E2 (Oestradiol) < 118pmol/L and FSH >30 IU/L.
Who may be able to join
- Biological woman, 18-65 years of age
- Body mass index (BMI) 18-30 kg/m2
- Non smoker
- Not performing regular resistance type exercise
- Participant is willing and able to give informed consent for participation in the study
Who cannot join
- A BMI <18 or >39 kg·m-2
- Active cardiovascular disease: uncontrolled hypertension (Blood pressure > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event.
- Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)
- Respiratory disease including pulmonary hypertension or Chronic obstructive pulmonary disease (COPD).
- Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), polycystic ovarian syndrome (PCOS), inborn/ congenital errors of metabolism (e.g. Phenylketonuria (PKU), galactosaemia)
- Active inflammatory bowel disease.
Show all 17Show fewer
- Acute infection.
- Acute or chronic renal disease.
- Malignancy (or history of malignancy with 5 y).
- Recent (within 6 mo) or current steroid treatment, hormone replacement therapy (HRT), hormonal contraception, or other hormonal therapies that may interfere with outcome measures.
- Coagulopathy.
- Musculoskeletal or neurological disorders.
- Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance.
- Amenorrhoea for a reason other than menopause.
- Contraindications for Magnetic Resonance Imaging (MRI).
- Allergy or sensitivity to local anaesthesia, or dressing adhesive.
- Inner ear pathology or vertigo
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Campbell Menzies contact
United Kingdom1 site, 1 recruiting
- Recruiting
Queens Medical Centre Campus
Nottingham
Matthew Brook, 0115 8230248, Matthew.Brook@nottingham.ac.uk
Matthew Brook, PhD
About this study
Aging causes muscles to often become smaller and weaker resulting in physical frailty and functional impairments, such as difficulty raising from a chair, dressing, and preparing meals. In the UK there is a growing aged population with those >65y expected to increase from 18% of the population in 2016, to 26% by 2066. As such, age related muscle mass loss and functional impairments represents one of the largest problems facing the health care services. There is an urgent need to develop strategies to reduce healthcare costs and improve health and wellbeing with age. These strategies must be targeted, as evidence suggests that the loss in muscle size and strength is different between men and women throughout the aging process. For example, older women have greater levels of physical disability that includes difficulties in walking around the home, getting out of a bed or chair, and eating, compared with men. These sex differences with ageing are unclear, yet the greater levels of physical disability could be the result of the menopause. The menopause describes a change in the sex hormone environment that is a part of normal female ageing. Physical disability can be further enhanced by an increase in body fat during the menopause in the face of decreasing muscle mass. Currently, there is a lack of understanding as to how these changes in body composition occur, with no effective treatments against muscle mass loss. The aims of this project are to increase understanding on how the menopause impacts muscle mass regulation. In addition, the investigators will use novel magnetic resonance imaging (MRI) techniques to map the distribution of newly created fat, and qualitative interviews to better understand how resistance exercise therapy (RET) can be incorporated into the daily lives of postmenopausal women.
Read the detailed description
The age-related loss of muscle mass and function (sarcopenia) inevitably results in physical frailty and functional impairments, such as difficulty raising from a chair, dressing, and preparing meals. With a rapidly growing aged population (those >65y increasing from 18% of the population in 2016, to 26% by 2066), sarcopenia represents one of the largest problems facing health care services. Excess healthcare costs associated with sarcopenia are rapidly growing and were estimated to be £2.5 billion in 2016. There is an urgent need to develop strategies to mitigate sarcopenia to reduce healthcare costs and improve health and wellbeing with age. These strategies must be targeted, as evidence suggests that there is sexual dimorphism in ageing and the development of sarcopenia. Sarcopenia develops earlier in women, resulting in greater levels of physical disability that includes difficulties in walking, getting out of a chair, and eating, compared with men. The mechanistic sex differences with ageing are unclear, yet the earlier prevalence of sarcopenia in women coincides with the menopause. In addition, physical disability can be further exacerbated by an increase in adiposity during the menopause in the face of decreasing muscle mass. This change in body composition includes ectopic fat infiltration into muscle that is associated with decreased muscle performance, however, currently, there is a lack of understanding as to how these changes in body composition occur.
Understanding the underlying mechanisms that bring about change in physiological systems is key in the development of interventions. Muscle mass is controlled by the balance between muscle protein synthesis (MPS) and muscle protein breakdown (MPB). With age, many of the signals that increase MPS (i.e., nutrient intake and activity) become less effective, resulting in negative protein balance and muscle loss. Since muscle loss is accelerated after the menopause in women, there must be a greater imbalance between MPS and MPB. The measurement of MPS and MPB can be achieved using stable isotope tracer techniques that can be followed throughout the body. However, there is a lack of research into the mechanistic effects of the menopause on muscle mass regulation. In addition to measures of muscle protein turnover, the investigators have recently used stable isotope tracer techniques alongside MRI scanning to image deuterium incorporation within lipid. the investigators will use these techniques to image newly created fat to further understanding of body composition changes in post-menopausal women.
Resistance exercise therapy (RET) currently offers the most effective strategy to mitigate muscle mass loss and improve body composition with ageing, by increasing MPS, promoting muscle hypertrophy, and building strength8. However, older women display blunted muscle hypertrophy in response to RET (when compared to younger women, and older men), and it is not known how the menopause affects hypertrophic responses to exercise. Further, for any intervention to have a meaningful impact, it must be effectively incorporated by postmenopausal women into their daily lives. The investigators have conducted an evaluation of physical activity interventions for post-menopausal women, which revealed that women going through the menopause want more evidence-based guidance on how much and what type of exercise they should be doing, and on whether exercise can alleviate menopausal symptoms and prevent muscle loss.
Aims: To investigate the effects of the menopause on muscle mass regulation, changes in body composition, and assess the acceptability and effectiveness of RET.
- Conditions
- Healthy
- Being tested
- Unilateral Resistance Exercise
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Unilateral Resistance ExerciseBehavioural
Resistance exercise training session, consisting of 6 x 8 repetitions of leg extension (of the non-dominant leg) at 75% 1RM (repetition maximum) with 2 min rest between sets.
| Study group | Role | What they receive |
|---|---|---|
| Premenopausal | Defined as having a menstrual cycle and having plasma follicle-stimulating hormone (FSH) <30 IU/L, taken during days 1-5 of their menstrual cycle. Receives: Behavioral: Unilateral Resistance Exercise | |
| Postmenopausal | Defined as having no menses for 12 months, E2 (Oestradiol) < 118pmol/L and FSH >30 IU/L. Receives: Behavioral: Unilateral Resistance Exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of muscle protein synthesis
Comparison between pre and post menopausal women of vastus lateralis muscle protein synthesis in response to acute unilateral resistance exercise and at rest using deuterium oxide stable isotope techniques.
Measured: 3 Days
Rate of muscle protein breakdown
Comparison between pre and post menopausal women of whole body muscle protein breakdown in response to acute unilateral resistance exercise and at rest using D3-3-methylhistidine
Measured: 3 Days
Secondary outcomes (7)
Whole body muscle mass
Comparison between pre and post menopausal women of whole body muscle mass using D3-Creatine
Measured: At the point of enrolment
Quadriceps fat mass
Comparison between pre and post menopausal women of quadriceps fat using Dixon magnetic resonance imaging (MRI) of the quadriceps
Measured: At the point of enrolment
Menopausal symptoms
Comparison between pre and post menopausal women of menopausal symptoms on the menopause rating scale (0 - 44; higher score = greater menopause symptoms)
Measured: At the point of enrolment
Knee extensor strength
Comparison between pre and post menopausal women of knee extensor muscle strength in response to unilateral exercise training using a cybex dynamometer
Measured: At the point of enrolment
De novo lipogenesis
Use deuterium magnetic resonance imaging (MRI) to map the distribution of newly created lipid in pre and post menopausal women.
Measured: 0 - 8 weeks
Intramuscular protein signalling
Comparison between pre and post menopausal women of intramuscular protein signalling in response to unilateral resistance exercise using immunoblotting.
Measured: 0 - 3 Days
Muscle gene expression
Comparison between pre and post menopausal women of muscle messenger ribonucleic acid (mRNA) gene expression in response to unilateral resistance exercise using polymerase chain reactions (PCR).
Measured: 0 - 3 Days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2025
- Study start29 Jul 2024
- Primary completionMar 2026 (estimated)
- Study completionMar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University of NottinghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Collaborators
- Medical Research Council
- Responsible party
- Principal investigator, Matthew Brook, University of Nottingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06806501
- Sponsor's protocol ID
- FMHS 129-0224
- Status last verified
- Jan 2025
- First submitted
- 18 Jun 2024
- Last updated
- 4 Feb 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Muscle Mass, Quality, and the Menopause: Sex-specific Strategies to Mitigate Sarcopenia in Ageing Populations
- ClinicalTrials.gov ID
- NCT06806501
- Acronym / sponsor ID
- FMHS 129-0224
- Conditions
- Healthy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Collaborators
- Medical Research Council
- Study start
- 29 Jul 2024 (actual)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Mar 2026 (estimated)
- First posted
- 4 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aging causes muscles to often become smaller and weaker resulting in physical frailty and functional impairments, such as difficulty raising from a chair, dressing, and preparing meals. In the UK there is a growing aged population with those >65y expected to increase from 18% of the population in 2016, to 26% by 2066. As such, age related muscle mass loss and functional impairments represents one of the largest problems facing the health care services. There is an urgent need to develop strategies to reduce healthcare costs and improve health and wellbeing with age. These strategies must be targeted, as evidence suggests that the loss in muscle size and strength is different between men and women throughout the aging process. For example, older women have greater levels of physical disability that includes difficulties in walking around the home, getting out of a bed or chair, and eating, compared with men. These sex differences with ageing are unclear, yet the greater levels of physical disability could be the result of the menopause. The menopause describes a change in the sex hormone environment that is a part of normal female ageing. Physical disability can be further enhanced by an increase in body fat during the menopause in the face of decreasing muscle mass. Currently, there is a lack of understanding as to how these changes in body composition occur, with no effective treatments against muscle mass loss. The aims of this project are to increase understanding on how the menopause impacts muscle mass regulation. In addition, the investigators will use novel magnetic resonance imaging (MRI) techniques to map the distribution of newly created fat, and qualitative interviews to better understand how resistance exercise therapy (RET) can be incorporated into the daily lives of postmenopausal women.
Detailed description
The age-related loss of muscle mass and function (sarcopenia) inevitably results in physical frailty and functional impairments, such as difficulty raising from a chair, dressing, and preparing meals. With a rapidly growing aged population (those >65y increasing from 18% of the population in 2016, to 26% by 2066), sarcopenia represents one of the largest problems facing health care services. Excess healthcare costs associated with sarcopenia are rapidly growing and were estimated to be £2.5 billion in 2016. There is an urgent need to develop strategies to mitigate sarcopenia to reduce healthcare costs and improve health and wellbeing with age. These strategies must be targeted, as evidence suggests that there is sexual dimorphism in ageing and the development of sarcopenia. Sarcopenia develops earlier in women, resulting in greater levels of physical disability that includes difficulties in walking, getting out of a chair, and eating, compared with men. The mechanistic sex differences with ageing are unclear, yet the earlier prevalence of sarcopenia in women coincides with the menopause. In addition, physical disability can be further exacerbated by an increase in adiposity during the menopause in the face of decreasing muscle mass. This change in body composition includes ectopic fat infiltration into muscle that is associated with decreased muscle performance, however, currently, there is a lack of understanding as to how these changes in body composition occur.
Understanding the underlying mechanisms that bring about change in physiological systems is key in the development of interventions. Muscle mass is controlled by the balance between muscle protein synthesis (MPS) and muscle protein breakdown (MPB). With age, many of the signals that increase MPS (i.e., nutrient intake and activity) become less effective, resulting in negative protein balance and muscle loss. Since muscle loss is accelerated after the menopause in women, there must be a greater imbalance between MPS and MPB. The measurement of MPS and MPB can be achieved using stable isotope tracer techniques that can be followed throughout the body. However, there is a lack of research into the mechanistic effects of the menopause on muscle mass regulation. In addition to measures of muscle protein turnover, the investigators have recently used stable isotope tracer techniques alongside MRI scanning to image deuterium incorporation within lipid. the investigators will use these techniques to image newly created fat to further understanding of body composition changes in post-menopausal women.
Resistance exercise therapy (RET) currently offers the most effective strategy to mitigate muscle mass loss and improve body composition with ageing, by increasing MPS, promoting muscle hypertrophy, and building strength8. However, older women display blunted muscle hypertrophy in response to RET (when compared to younger women, and older men), and it is not known how the menopause affects hypertrophic responses to exercise. Further, for any intervention to have a meaningful impact, it must be effectively incorporated by postmenopausal women into their daily lives. The investigators have conducted an evaluation of physical activity interventions for post-menopausal women, which revealed that women going through the menopause want more evidence-based guidance on how much and what type of exercise they should be doing, and on whether exercise can alleviate menopausal symptoms and prevent muscle loss.
Aims: To investigate the effects of the menopause on muscle mass regulation, changes in body composition, and assess the acceptability and effectiveness of RET.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Premenopausal | – | Behavioral: Unilateral Resistance ExerciseDefined as having a menstrual cycle and having plasma follicle-stimulating hormone (FSH) <30 IU/L, taken during days 1-5 of their menstrual cycle. |
| Postmenopausal | – | Behavioral: Unilateral Resistance ExerciseDefined as having no menses for 12 months, E2 (Oestradiol) < 118pmol/L and FSH >30 IU/L. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be healthy females aged 18 - 65, who are not on hormonal replacement therapy or hormonal contraceptives and are not participating in regular resistance exercise. Participants will fall into two groups: * Premenopausal, defined as having a menstrual cycle and having plasma follicle-stimulating hormone (FSH) <30 IU/L, taken during days 1-5 of their menstrual cycle. * Postmenopausal, defined as having no menses for 12 months, E2 (Oestradiol) < 118pmol/L and FSH >30 IU/L.
Key inclusion criteria (5 listed)
- Biological woman, 18-65 years of age
- Body mass index (BMI) 18-30 kg/m2
- Non smoker
- Not performing regular resistance type exercise
- Participant is willing and able to give informed consent for participation in the study
Key exclusion criteria (17 listed)
- A BMI <18 or >39 kg·m-2
- Active cardiovascular disease: uncontrolled hypertension (Blood pressure > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event.
- Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)
- Respiratory disease including pulmonary hypertension or Chronic obstructive pulmonary disease (COPD).
- Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), polycystic ovarian syndrome (PCOS), inborn/ congenital errors of metabolism (e.g. Phenylketonuria (PKU), galactosaemia)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Unilateral Resistance ExerciseResistance exercise training session, consisting of 6 x 8 repetitions of leg extension (of the non-dominant leg) at 75% 1RM (repetition maximum) with 2 min rest between sets. | Behavioural | Postmenopausal, Premenopausal |
Primary outcome
Rate of muscle protein synthesis
Time frame: 3 Days
Comparison between pre and post menopausal women of vastus lateralis muscle protein synthesis in response to acute unilateral resistance exercise and at rest using deuterium oxide stable isotope techniques.
Rate of muscle protein breakdown
Time frame: 3 Days
Comparison between pre and post menopausal women of whole body muscle protein breakdown in response to acute unilateral resistance exercise and at rest using D3-3-methylhistidine
7 secondary outcomes
Whole body muscle mass
Time frame: At the point of enrolment
Quadriceps fat mass
Time frame: At the point of enrolment
Menopausal symptoms
Time frame: At the point of enrolment
Knee extensor strength
Time frame: At the point of enrolment
De novo lipogenesis
Time frame: 0 - 8 weeks
Intramuscular protein signalling
Time frame: 0 - 3 Days
Muscle gene expression
Time frame: 0 - 3 Days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2025.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Campbell Menzies contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy, run by University of Nottingham at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Matthew Brook (0115 8230248, Matthew.Brook@nottingham.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of muscle protein synthesis (time frame: 3 Days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2025.